文献速递头颈外科

头颈部鳞状细胞癌中西妥昔单抗单药治疗应答的免疫基因组学相关因素

Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma.
PubMed 文献 · Head Neck · 2019-03-04

研究对20例接受新辅助西妥昔单抗单药治疗的前瞻性试验HNSCC肿瘤行全外显子测序,发现无应答者HLA-C突变率高于应答者及TCGA中528例HNSCC肿瘤(P<0.00001)。体外实验显示西妥昔单抗激活的NK细胞经干扰素γ上调HNSCC细胞HLA-C(P<0.01),抗KIR单抗lirilumab处理NK细胞增加对HNSCC细胞的杀伤(P<0.001)。结论认为HLA-C改变可能通过破坏NK激活提供免疫逃逸机制。

要点

  • 西妥昔单抗无应答者HLA-C突变率高于应答者及TCGA肿瘤(P<0.00001)。
  • 西妥昔单抗激活NK细胞经干扰素γ上调HNSCC细胞HLA-C(P<0.01)。
  • lirilumab处理NK细胞增加对HNSCC细胞杀伤(P<0.001)。

核心结论

  • HLA-C改变可能通过破坏NK激活提供免疫逃逸机制。

研究设计与样本

  • 前瞻性西妥昔单抗新辅助单药治疗试验中20例HNSCC肿瘤行全外显子测序,并在HNSCC细胞系评估KIR与HLA-C表达及KIR阻断效果。

主要发现

  • 西妥昔单抗无应答者HLA-C突变率高于应答者及TCGA中528例HNSCC肿瘤(P<0.00001)。
  • 体外西妥昔单抗激活的NK细胞经干扰素γ上调HNSCC细胞HLA-C(P<0.01)。
  • 抗KIR单抗lirilumab处理NK细胞增加对HNSCC细胞杀伤(P<0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Mechanisms of resistance to immune-modulating cancer treatments are poorly understood. Using a novel cohort of patients with head and neck squamous cell carcinoma (HNSCC), we investigated mechanisms of immune escape from epidermal growth factor receptor-specific monoclonal antibody (mAb) therapy. METHODS: HNSCC tumors (n = 20) from a prospective trial of neoadjuvant cetuximab monotherapy underwent whole-exome sequencing. Expression of killer-cell immunoglobulin-like receptor (KIR) and human leukocyte antigen-C (HLA-C) and the effect of KIR blockade were assessed in HNSCC cell lines. RESULTS: Nonresponders to cetuximab had an increased rate of mutations in HLA-C compared to responders and HNSCC tumors (n = 528) in The Cancer Genome Atlas (P < 0.00001). In vitro, cetuximab-activated natural killer (NK) cells induced upregulation of HLA-C on HNSCC cells (P < 0.01) via interferon gamma. Treatment of NK cells with the anti-KIR mAb lirilumab increased killing of HNSCC cells (P < 0.001). CONCLUSIONS: Alterations in HLA-C may provide a mechanism of immune evasion through disruption of NK activation.

来源:Head Neck,查看原文。版权归原作者所有。

引用

  1. Faden DL, Concha-Benavente F, Chakka AB, et al. Immunogenomic correlates of response to cetuximab monotherapy in head and neck squamous cell carcinoma. Head Neck. 2019. PMID: 30828910. doi:10.1002/hed.25726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。